Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
February 2024
in “
Cancers
”
Studysummary This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges. Our plain-language summary of this paper — not a Tressless recommendation.
The document "Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer" reviews the development of androgen receptor (AR) degraders, particularly PROTACs, for treating castration-resistant prostate cancer (CRPC). It highlights the progress of ARV-110 and ARV-766, which have reached phase II clinical trials, and other degraders in phase I trials. These degraders work by breaking down the AR protein, crucial for cancer progression, and show promise in overcoming resistance to traditional therapies. The review emphasizes the importance of understanding AR–PROTAC–ligase complexes and the potential of these novel agents to improve treatment outcomes for CRPC patients.
